but next time on zero max find out something week celebrating the guild bosley says inverted style asthe artist turns. french design a month seems in lynn sweet follows the legendary house of oz the whole. time scratch the designers in back is unique three deep in the structure. next time on your own max time. the african country the kenyan fossil wants to be a pioneer in so little energy. it's all thanks to the social entrepreneur princes come see. all this one still look at. the local solutions created for the people yet by the people here that's also part of our goal to show the new face of dictionary possible that eco africa thirty minutes on d w. one argues policy it's a real policy because there is no rubbishing about everyone rights that only and on their own cut and then we part. and you know what the great thing is you know and they. freedom of expression. a value that a ways has to be defended and new. all over the world. are to afraid of freedom of art. a multimedia project about artists and their right to express their views freely. d w dot com to freedom. climate change.

take it away >> mel, thanks so much joining us is katrine bosley this seems to be affecting your stockore stocks working in this exciting gene editing technology essentially whether people have an existing immunity to this technology how due look at that research? >> we actually don't see this as an issue in the field of genome editing, sometimes when they publications come out, you'll see a little reaction, we seen that bev at editas, we're focused on doing that translational worm to advance experimental medicines into studies with people we have done a lot of work on this specific topic, and we don't see this as an issue >> you announced today you have fife medicines in the next five years. this is a really new technology. we are excited morgan of our fi years goal to advance into studies of people over the next five years we have been building our capabilities in science the last four years and we feel well positioned to do this in a range of diseases. our first program treats inherited form of blindness and other programs we expect to advance in cancer and diseases in the blood suc